<DOC>
	<DOCNO>NCT00119431</DOCNO>
	<brief_summary>A multicentre study investigate pharmacokinetics , clinical efficacy safety nanofiltered Cetor® ( call C1-esteraseremmer-N development phase ) treatment hereditary angioedema ( HAE ) perform . This study KB2003.01 consist three part , part A pharmacokinetics ( phase II ) , part B treatment attack angioedema ( phase III ) part C prophylactic use C1 inhibitor ( phase III ) . Part B + C provide data efficacy C1-esteraseremmer-N . The change manufacture process C1-esteraseremmer-N , compare Cetor® ( currently market C1-inhibitor product ) , nanofiltration omission hepatitis B immunoglobulin , likely affect tolerability . The nanofiltration provide safety regard virus . In part A , pharmacokinetics C1-esteraseremmer-N patient hereditary angioedema compare current registered product , Cetor® , randomise , blind cross-over design . This study provide evidence change manufacture process affect pharmacokinetics . In addition , study provide data safety C1-esteraseremmer-N .</brief_summary>
	<brief_title>Kinetics , Efficacy Safety C1-Esteraseremmer-N</brief_title>
	<detailed_description>A multicentre study investigate pharmacokinetics , clinical efficacy safety nanofiltered Cetor® ( call C1-esteraseremmer-N development phase ) treatment hereditary angioedema ( HAE ) perform . This study KB2003.01 consist three part , part A pharmacokinetics ( phase II ) , part B treatment attack angioedema ( phase III ) part C prophylactic use C1 inhibitor ( phase III ) . Part B + C provide data efficacy C1-esteraseremmer-N . The change manufacture process C1-esteraseremmer-N , compare Cetor® ( currently market C1-inhibitor product ) , nanofiltration omission hepatitis B immunoglobulin , likely affect tolerability . The nanofiltration provide safety regard virus . In part A , pharmacokinetics C1-esteraseremmer-N patient hereditary angioedema compare current registered product , Cetor® , randomise , blind cross-over design . This study provide evidence change manufacture process affect pharmacokinetics . In addition , study provide data safety C1-esteraseremmer-N. Twelve HAE patient without sign attack receive administration 1,000 U , 1,500 U 2,000 U C1-esteraseremmer-N Cetor® later dose product . Both antigenic functional C1 inhibitor level determine . Laboratory safety parameter adverse event monitor well</detailed_description>
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Hereditary Angioedema Types I II</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<criteria>Established diagnosis hereditary angioedema type I : i.e . markedly decrease C1 inhibitor activity , decrease level C1 inhibitor antigen decrease level C4 . Age ≥ 18 year Body weight 40 100 kg . Signed Informed consent C1 inhibitor infusion within last 7 day Signs attack Angioedema attack within 7 day actual infusion study medication Change dosage androgen last 14 day study Change oral anticonceptive medication last two month study Pregnancy lactation . Bcell malignancy Participation another pharmaceutical clinical study , interfere study , last 3 month prior study History clinically relevant antibody development C1 inhibitor Use oral anticoagulant medication last 14 day Use heparin within last two day prior study History allergic reaction C1 inhibitor concentrate blood product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Hereditary angioedema type I ( MeSH : angioneurotic edema , complement 1 inactivators )</keyword>
</DOC>